Danish Biotech Weekly – Week 26

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Zealand Pharma and Fluoguide posted very positive phase II results paving the way for further studies, and CS Medica signed a contract regarding their pain patch for the Spanish and Portugese markets. Many companies experienced declining share prices without posting any news.

Only 4 of the 20 listed, Danish biotech companies published news the past week. 3 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Saniona is still the best performing stock this year.

Company news the past week

Ascendis Pharma

No news the past week


No news the past week


No news the past week

CS Medica

CS MEDICA A/S Signs New Own-Label Agreement on Pain Patch (Link)


No news the past week

Evaxion Biotech

No news the past week


No news the past week


FluoGuide announces positive interim results from phase IIa trial of FG001 in head & neck cancer (Link)


Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’ (Link)


No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week


No news the past week

Zealand Pharma

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906) (Link)

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech stocks delivered a negative share price performance last week of -5.6%. In the past week, Fluoguide became the best performing stock with an 5% increase after a positive phase IIa trial of FG001 in head & neck cancer. Data showed all 12 patients had their tumors lit up with FG001. Cessatech and Expres2ion were the only Danish biotech stocks that also delivered a positive return in the past week. On the other end of the spectre, Saniona AB became the worst performing stock with a 22% decrease without posting any news. However, it may be due to the fact that the share has already taken off in 2023 with a 178% increase. Curasight A/S, Zealand Pharma A/S and Saniona AB continue to be the best performing stocks year-to-date after soaring 136-178% after among other things partnerships and positive recommendations from authorities paving the way for approvals. The Danish biotech stocks have done great year-to-date with a total return of 8.2%.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.